Monteverde & Associates PC is investigating four merger transactions: LiveRamp Holdings' sale to Publicis Groupe for $38.50/share, NextEra Energy's merger with Dominion Energy, Centessa Pharmaceuticals' acquisition by Eli Lilly for $38.00/share plus contingent value rights, and HCB Financial's merger with Independent Bank Corporation. The firm is seeking shareholders to join class action lawsuits related to these deals.

Nxera Pharma reported strong Q1 2026 results with revenue of JPY 11.3 billion, a significant increase from the prior year, driven by seven R&D milestone events. The company signed a licensing agreement with Santhera for vamorolone in APAC markets, achieved positive Phase 3 results for daridorexant in South Korea, and received milestone payments from Neurocrine and AbbVie. Additionally, Centessa Pharmaceuticals (spun out from Nxera in 2019) agreed to be acquired by Eli Lilly for up to $7.8 billion, with Nxera retaining rights to milestone and royalty payments.

While Eli Lilly is known for its weight loss drug dominance with Zepbound and Mounjaro, the article highlights the company's underappreciated diversification across oncology, immunology, and neuroscience. With blockbuster drugs like Verzenio ($5.7B sales) and Taltz ($3.6B sales), plus strategic acquisitions in gene therapy and other areas, Eli Lilly is better positioned than competitors like Novo Nordisk to weather competition and drive long-term growth beyond its current weight-loss market leadership.

Eli Lilly announced a $6.3 billion acquisition of U.K.-based Centessa Pharmaceuticals, a clinical-stage biotech focused on neuroscience. The deal includes up to $1.5 billion in milestone payments tied to Centessa's lead drug candidate cleminorexton for sleep-wake disorders. Despite the large price tag, Lilly's stock reacted positively due to the company's strong financial position, bolstered by the success of weight-loss drugs Zepbound and Mounjaro. The acquisition represents Lilly's strategy of both building and acquiring assets for continued growth.

A major M&A week sees Sysco acquiring Restaurant Depot for $26 billion and McCormick merging with Unilever's food division for $44 billion, while Eli Lilly acquires Centessa Pharmaceuticals for $7.8 billion. The podcast discusses the track record of consumer brand mergers (mostly unsuccessful) and analyzes Whirlpool as a dividend investment amid housing market headwinds.

Major M&A activity dominates the market with McCormick merging with Unilever's Foods business in a $29.1 billion deal, Sysco acquiring Jetro Restaurant Depot for $29 billion, and Eli Lilly acquiring Centessa Pharmaceuticals for $7.8 billion. Meanwhile, QVC faces financial distress and is considering Chapter 11 bankruptcy, while several other companies including IO Biotech and Lipella Pharmaceuticals have filed for bankruptcy.

Eli Lilly commits over $10 billion to two major strategic initiatives: a $2.75 billion expanded partnership with InSilico Medicine to leverage AI for drug discovery, and a $6.3-7.8 billion acquisition of Centessa Pharmaceuticals to enter the sleep-wake disorders market. These moves aim to modernize R&D processes, diversify revenue beyond its GLP-1 franchise, and support the company's premium valuation.

Eli Lilly and Company has agreed to acquire Centessa Pharmaceuticals, which developed an OX2R agonist pipeline for sleep-wake disorders in collaboration with Nxera Pharma. Nxera retains material economic interests including milestone payments, royalties, and an equity stake in Centessa. The acquisition validates Nxera's drug discovery platform and complements Nxera's existing multi-target collaboration with Lilly worth up to $694 million in potential milestones.

Eli Lilly has agreed to acquire Centessa Pharmaceuticals, which is developing an OX2R agonist pipeline for sleep-wake disorders jointly discovered with Nxera. Nxera retains milestone payments, royalties, and an equity interest in Centessa under the transaction. Nxera also maintains a separate collaboration with Lilly on metabolic disease drug discovery.

Eli Lilly agreed to acquire Centessa Pharmaceuticals for approximately $6.3 billion upfront plus up to $1.5 billion in contingent payments. The acquisition expands Lilly's neuroscience portfolio with Centessa's orexin receptor 2 agonist pipeline, including the lead candidate cleminorexton for sleep disorders. The deal is expected to close in Q3 pending shareholder and regulatory approval. Centessa shares surged 45% on the announcement.

While Centessa Pharmaceuticals shows promise with its ORX750 narcolepsy candidate, the article argues that Vertex Pharmaceuticals is a superior investment choice. Vertex has an established profitable business in cystic fibrosis, recent successful launches like Journavx and Casgevy, and a strong late-stage pipeline including zimislecel for Type 1 diabetes. Centessa, as a pre-revenue biotech, carries significantly higher risk despite its promising pipeline.

Commodore Capital significantly reduced its stake in Centessa Pharmaceuticals by selling 1.85 million shares (worth ~$46.86 million) in Q4, cutting its position from over 9% to 1.66% of assets. The sale comes as CNTA stock has surged 53.4% over the past year. The fund's move suggests capital redeployment amid Centessa's strategic shift toward focusing on its orexin franchise under new CEO Mario Accardi, raising questions about concentration risk versus the potential of the company's narrowed pipeline.